Abstract

IntroductionTreatment options for platinum-resistant ovarian cancer (PROC) remain a high medical need. Mesothelin is highly expressed in PROC. Anetumab ravtansine (ARv) is an antibody–drug conjugate that selectively targets mesothelin, consisting...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
...
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. Suppl 23 10
, et. al. ...
23 Dec 2022
Apatinib combined with pegylated liposomal doxorubicin (PLD) versus PLD for platinum-resistant recurrent ovarian cancer (APPROVE): a multicenter, randomized, controlled, open-label, phase II trial
Tiantian Wang ... Lingying Wu
Gynecologic oncology | VOL. 162
Tiantian Wang, et. al.Tiantian Wang ... Lingying Wu
01 Aug 2021
Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)
Ursula Matulonis ... Robert Coleman
Gynecologic oncology | VOL. 166
Ursula Matulonis, et. al.Ursula Matulonis ... Robert Coleman
01 Aug 2022
The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?
David E Cohn ... William S Shimp
Gynecologic Oncology Reports | VOL. 13
David E Cohn, et. al.David E Cohn ... William S Shimp
25 Jun 2015
View more papers

More From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Paper Title
Journal
Date
Author
Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA
Giorgia Dinoi ... Francesco Fanfani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Giorgia Dinoi, et. al.Giorgia Dinoi ... Francesco Fanfani
13 Jul 2024
Role of V-Y flap reconstruction in vulvar cancer patients: multicenter retrospective study
Violante Di Donato ... Giorgio Bogani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Violante Di Donato, et. al.Violante Di Donato ... Giorgio Bogani
13 Jul 2024
Higher incidence of venous thromboembolism associated with increasing lines of treatment in heavily treated ovarian cancer patients
Erika J Lampert ... Mariam M Alhilli
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Erika J Lampert, et. al.Erika J Lampert ... Mariam M Alhilli
13 Jul 2024
Antibody–drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer
Antonio Gonzalez-Martin
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Antonio Gonzalez-MartinAntonio Gonzalez-Martin
10 Jul 2024
View more papers